留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

类风湿性关节炎的治疗药物研究进展

王静,  赵庆杰,  卓小斌,  姜云云,  叶光明

downloadPDF
文章导航 > 药学实践与服务  > 2019 >  37(6): 485-490
王静, 赵庆杰, 卓小斌, 姜云云, 叶光明. 类风湿性关节炎的治疗药物研究进展[J]. 药学实践与服务, 2019, 37(6): 485-490. doi: 10.3969/j.issn.1006-0111.2019.06.002
引用本文: 王静, 赵庆杰, 卓小斌, 姜云云, 叶光明. 类风湿性关节炎的治疗药物研究进展[J]. 药学实践与服务, 2019, 37(6): 485-490. doi: 10.3969/j.issn.1006-0111.2019.06.002
shu
WANG Jing, ZHAO Qinjie, ZHUO Xiaobin, JIANG Yunyun, YE Guangming. Research progress on therapeutic drugs for rheumatoid arthritis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 485-490. doi: 10.3969/j.issn.1006-0111.2019.06.002
Citation: WANG Jing, ZHAO Qinjie, ZHUO Xiaobin, JIANG Yunyun, YE Guangming. Research progress on therapeutic drugs for rheumatoid arthritis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 485-490. doi: 10.3969/j.issn.1006-0111.2019.06.002
shu

类风湿性关节炎的治疗药物研究进展

doi: 10.3969/j.issn.1006-0111.2019.06.002
  • 1.

    安徽医科大学解放军98临床学院, 浙江 湖州 230032

  • 2.

    海军军医大学药学院, 上海 200433

  • 3.

    解放军101医院, 江苏 无锡 214044

Research progress on therapeutic drugs for rheumatoid arthritis

  • 1.

    Huzhou Clinical College of Auhui medical University/No. 98 Hospital of PLA, Huzhou 230032, China

  • 2.

    School of Pharmacy, Naval Medical University, Shanghai 200433, China

  • 3.

    No. 101 Hospital of PLA, Wuxi 214044, China

  • 摘要: 类风湿性关节炎（RA）作为一种常见的自身免疫性疾病，临床表现为关节损伤和滑膜炎症。通过阐述临床RA药物的治疗机制和作用靶点，综述了两大类RA药物，包括小分子合成类RA药物和大分子生物RA药物（肿瘤坏死因子α抑制剂、T、B细胞抑制剂、细胞因子受体抑制剂、靶点RANKL生物制剂以及靶点粒细胞-巨噬细胞集落刺激因子生物制剂），通过结合RA病理机制重点对这两大类药物的治疗机制和作用靶点进行阐明介绍，同时概述了治疗类风湿性关节炎的最新治疗靶点，为类风湿性关节炎患者的治疗提供潜在新方向。
    Abstract: Rheumatoid arthritis (RA) is a common autoimmune disease characterized by joint damage and synovial inflammation.Two major classes of RA drugs,including small molecule synthetic RA drugs and macromolecular biological RA drugs (TNF inhibitors、B cell inhibitors、T cell inhibitors、IL inhibitors、target RANKL biologics、target GM-CSF biologics) were reviewed in this paper,focusing on the therapeutic mechanisms of these two classes of drugs.In addition the latest therapeutic target for rheumatoid arthritis was also summarized,which provided a potential new direction for the treatment of patients with rheumatoid arthritis.
  • [1] CROSS M,SMITH E,HOY D,et al.The global burden of rheumatoid arthritis:estimates from the global burden of disease 2010 study[J].Ann Rheum Dis,2014,73(7):1316-1322.
    [2] SCHELLEKENS G A,DE JONG B A,VAN DEN HOOGEN F H,et al.Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies[J].J Clin Invest,1998,101(1):273-281.
    [3] SMOLEN J S,ALETAHA D,MCINNES I B.Rheumatoid arthritis[J].Lancet,2016,388(10055):2023-2038.
    [4] VISSER K,VAN DER HEIJDE D.Optimal dosage and route of administration of methotrexate in rheumatoid arthritis:a systematic review of the literature[J].Ann Rheum Dis,2009,68(7):1094-1099.
    [5] BROWN P M,PRATT A G,ISAACS J D.Mechanism of action of methotrexate in rheumatoid arthritis,and the search for biomarkers[J].Nat Rev Rheumatol,2016,12(12):731-742.
    [6] HERRMANN M L,SCHLEYERBACH R,KIRSCHBAUM B J.Leflunomide:an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases[J].Immunopharmacology,2000,47(2-3):273-289.
    [7] STRAND V,COHEN S,SCHIFF M,et al.Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate.leflunomide rheumatoid arthritis investigators group[J].Arch Intern Med,1999,159(21):2542-2550.
    [8] LINARES V,ALONSO V,DOMINGO J L.Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity[J].Expert Opin Drug Saf,2011,10(2):253-263.
    [9] PLOSKER G L,CROOM K F.Sulfasalazine:a review of its use in the management of rheumatoid arthritis[J].Drugs,2005,65(13):1825-1849.
    [10] LEE C K,LEE E Y,CHUNG S M,et al.Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB,osteoprotegerin,and receptor activator of nuclear factor kappaB ligand[J].Arthritis Rheum,2004,50(12):3831-3843.
    [11] SAMES E,PATERSON H,LI C.Hydroxychloroquine-induced agranulocytosis in a patient with long-term rheumatoid arthritis[J].Eur J Rheumatol,2016,3(2):91-92.
    [12] KATZ S J,RUSSELL A S.Re-evaluation of antimalarials in treating rheumatic diseases:re-appreciation and insights into new mechanisms of action[J].Curr Opin Rheumatol,2011,23(3):278-281.
    [13] KIM J W,KIM YY,LEE H,et al.Risk of retinal toxicity in longterm users of hydroxychloroquine[J].J Rheumatol,2017,44(11):1674-1679.
    [14] YAMAOKA K,KUBO S,SONOMOTO K,et al.JAK inhibitor:tofacitinib,a new disease modifying anti-rheumatic drug[J].Inflamm Regen,2011,31(4):349-353.
    [15] SEMERANO L,DECKER P,CLAVEL G,et al.Developments with investigational Janus kinase inhibitors for rheumatoid arthritis[J].Expert Opin Investig Drugs,2016,25(12):1355-1359.
    [16] AND M F,MAINI R N.Anti-tnf alpha therapy of rheumatoid arthritis:what have we learned[J].Ann Rev Immunol,2001,19(1):163-196.
    [17] GAO G H,LI J,XIE H W,et al.Therapeutic effect of infliximab on moderate and severe active rheumatoid arthritis[J].J South Med Univ,2010,30(4):724-726.
    [18] BRAUN J,KAY J.The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis[J].Expert Opin Drug Saf,2017,16(3):289-302.
    [19] WEINBLATT M E,KEYSTONE E C,FURST D E,et al.Adalimumab,a fully human anti-tumor necrosis factor alpha monoclonal antibody,for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate:the ARMADA trial[J].Arthritis Rheum,2003,48(1):35-45.
    [20] WEINBLATT M E,KEYSTONE E C,FURST D E,et al.Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis:ARMADA 4 year extended study[J].Ann Rheum Dis,2006,65(6):753-759.
    [21] JAMAL S,PATRA K,KEYSTONE E C.Adalimumab response in patients with early versus established rheumatoid arthritis:DE019 randomized controlled trial subanalysis[J].Clin Rheumatol,2009,28(4):413-419.
    [22] SCHIFF M H,BURMESTER G R,KENT J D,et al.Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis[J].Ann Rheum Dis,2006,65(7):889-894.
    [23] YATES M,HAMILTON L E,ELENDER F,et al.Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial[J].J Rheumatol,2015,42(7):1177-1185.
    [24] ARENDS S,BROUWER E,EFDE M,et al.Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice[J].Clin Exp Rheumatol,2017,35(1):61-68.
    [25] KAY J,FLEISCHMANN R,KEYSTONE E,et al.Golimumab 3-year safety update:an analysis of pooled data from the long-term extensions of randomised,double-blind,placebo-controlled trials conducted in patients with rheumatoid arthritis,psoriatic arthritis or ankylosing spondylitis[J].Ann Rheum Dis,2015,74(3):538-546.
    [26] NESBITT A,FOSSATI G,BERGIN M,et al.Mechanism of action of certolizumab pegol(CDP870):in vitro comparison with other anti-tumor necrosis factor alpha agents[J].Inflamm Bowel Dis,2007,13(11):1323-1332.
    [27] MÉLET J,MULLEMAN D,GOUPILLE P,et al.Rituximab-induced T cell depletion in patients with rheumatoid arthritis:association with clinical response[J].Arthritis Rheum,2013,65(11):2783-2790.
    [28] 张凤,张玲玲,魏伟.B细胞活化因子及其受体介导的信号通路参与类风湿关节炎病理机制研究进展[J].中国免疫学杂志,2016,32(2):258-261.
    [29] JIN X Z,DING C H.Belimumab-an anti-BLyS human monoclonal antibody for rheumatoid arthritis[J].Expert Opin Biol Ther,2013,13(2):315-322.
    [30] CHEN L P,FLIES D B.Molecular mechanisms of T cell co-stimulation and co-inhibition[J].Nat Rev Immunol,2013,13(4):227-242.
    [31] RAIMONDO M G,BIGGIOGGERO M,CROTTI C,et al.Profile of sarilumab and its potential in the treatment of rheumatoid arthritis[J].Drug Des Dev Ther,2017,Volume 11:1593-1603.
    [32] 余琛琳,宗英,张晓芳,等.IL-1抑制剂研发策略及临床应用进展[J].中国新药杂志,2014,23(10):1121-1126.
    [33] CHIU Y G,RITCHLIN C T.Denosumab:targeting the RANKL pathway to treat rheumatoid arthritis[J].Expert Opin Biol Ther,2017,17(1):119-128.
    [34] YUE J,GRIFFITH J F,XIAO F,et al.Repair of bone erosion in rheumatoid arthritis by denosumab:A high-resolution peripheral quantitative computed tomography study[J].Arthritis Care Res (Hoboken),2017,69(8):1156-1163.
    [35] BURMESTER G R,MCINNES I B,KREMER J,et al.Arandomised phase IIb study of mavrilimumab,a novel GM-CSF receptor alpha monoclonal antibody,in the treatment of rheumatoid arthritis[J].Ann Rheum Dis,2017,76(6):1020-1030.
    [36] ELSHABRAWY H A,ESSANI A E,SZEKANECZ Z,et al.TLRs,future potential therapeutic targets for RA[J].Autoimmun Rev,2017,16(2):103-113.
    [37] FECHTNER S,FOX D A,AHMED S.Transforming growth factor β activated kinase 1:a potential therapeutic target for rheumatic diseases[J].Rheumatology (Oxford),2017,56(7):1060-1068.
    [38] CHEUNG TT,MCINNES I B.Future therapeutic targets in rheumatoid arthritis?[J].Semin Immunopathol,2017,39(4):487-500.
    [39] BENHAM H,NEL H J,LAW S C,et al.Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients[J].Sci Transl Med,2015,7(290):290ra87.
    [40] WHANG J A,CHANG B Y.Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis[J].Drug Discov Today,2014,19(8):1200-1204.
  • [1] 陈莹, 许子华, 胡北, 崔亚玲, 高欢, 吴琼.  通便灵胶囊治疗便秘的药效与机制研究 . 药学实践与服务, 2025, 43(1): 1-7. doi: 10.12206/j.issn.2097-2024.202404008
    [2] 李锐, 张倩倩, 王瑞冬, 高小峰.  国家集中带量采购政策下样本医院良性前列腺增生治疗药物使用情况分析 . 药学实践与服务, 2025, 43(2): 1-6. doi: 10.12206/j.issn.2097-2024.202408031
    [3] 马兹芬, 许维恒, 金煜翔, 薛磊.  食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
    [4] 夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞.  核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
    [5] 宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦.  脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
    [6] 陈怡君, 王卓, 何苗, 张宇, 田泾.  泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
    [7] 迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛.  负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
    [8] 张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一.  药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
    [9] 张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫.  基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
    [10] 杨贺英, 罗彩萍, 彭婷, 梁文仪, 沈颂章, 苏娟.  花椒生物碱富集纯化工艺优化及其成分分析 . 药学实践与服务, 2024, 42(): 1-7. doi: 10.12206/j.issn.2097-2024.202404066
    [11] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
    [12] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [13] 石晓萍, 吕迁洲, 李晓宇, 许青.  泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050
    [14] 段禹, 刘爱军.  活血化瘀法治疗血管性痴呆的研究进展 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202408045
    [15] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [16] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [17] 何亚伦, 祁智, 常杰.  消胀通便膏在晚期肝癌患者阿片类药物相关性便秘中的应用研究 . 药学实践与服务, 2024, 42(12): 520-523. doi: 10.12206/j.issn.2097-2024.202309009
    [18] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
    [19] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
    [20] 孙丹倪, 黄勇, 张嘉宝, 王培.  代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  7768
  • HTML全文浏览量:  1021
  • PDF下载量:  1231
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-06-03
  • 修回日期:  2019-10-09

类风湿性关节炎的治疗药物研究进展

doi: 10.3969/j.issn.1006-0111.2019.06.002
  • 1. 安徽医科大学解放军98临床学院, 浙江 湖州 230032
  • 2. 海军军医大学药学院, 上海 200433
  • 3. 解放军101医院, 江苏 无锡 214044
  • 收稿日期: 2019-06-03
  • 修回日期: 2019-10-09

摘要: 类风湿性关节炎（RA）作为一种常见的自身免疫性疾病，临床表现为关节损伤和滑膜炎症。通过阐述临床RA药物的治疗机制和作用靶点，综述了两大类RA药物，包括小分子合成类RA药物和大分子生物RA药物（肿瘤坏死因子α抑制剂、T、B细胞抑制剂、细胞因子受体抑制剂、靶点RANKL生物制剂以及靶点粒细胞-巨噬细胞集落刺激因子生物制剂），通过结合RA病理机制重点对这两大类药物的治疗机制和作用靶点进行阐明介绍，同时概述了治疗类风湿性关节炎的最新治疗靶点，为类风湿性关节炎患者的治疗提供潜在新方向。

English Abstract

王静, 赵庆杰, 卓小斌, 姜云云, 叶光明. 类风湿性关节炎的治疗药物研究进展[J]. 药学实践与服务, 2019, 37(6): 485-490. doi: 10.3969/j.issn.1006-0111.2019.06.002
引用本文: 王静, 赵庆杰, 卓小斌, 姜云云, 叶光明. 类风湿性关节炎的治疗药物研究进展[J]. 药学实践与服务, 2019, 37(6): 485-490. doi: 10.3969/j.issn.1006-0111.2019.06.002
shu
WANG Jing, ZHAO Qinjie, ZHUO Xiaobin, JIANG Yunyun, YE Guangming. Research progress on therapeutic drugs for rheumatoid arthritis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 485-490. doi: 10.3969/j.issn.1006-0111.2019.06.002
Citation: WANG Jing, ZHAO Qinjie, ZHUO Xiaobin, JIANG Yunyun, YE Guangming. Research progress on therapeutic drugs for rheumatoid arthritis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 485-490. doi: 10.3969/j.issn.1006-0111.2019.06.002
shu

    全文HTML

参考文献 (40)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计